Spero Therapeutics (SPRO) Assets (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Assets came in at $59.0 million in Q1 2026, down 24.05% YoY from $77.7 million in Q1 2025, and down 14.36% on a QoQ basis from $68.9 million in Q4 2025.
Spero Therapeutics (SPRO) Assets (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Assets data on file, last reported at $59.0 million in Q1 2026.
- Quarterly Assets fell 24.05% year-over-year to $59.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.0 million (down 24.05% YoY) and the FY2025 annual result came in at $68.9 million, down 37.65% from the prior year.
- Assets fell to $59.0 million in Q1 2026, from $68.9 million in the prior quarter.
- In the past five years, Assets ranged from a high of $182.4 million in Q4 2023 to a low of $54.2 million in Q3 2025.
- A 5-year average of $105.0 million and a median of $107.1 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2023 — Assets soared 66.11% — and 2025, when it slumped 59.92%.
- Tracing SPRO's Assets over 5 years: stood at $124.8 million in 2022, then surged by 46.14% to $182.4 million in 2023, then tumbled by 39.39% to $110.5 million in 2024, then sank by 37.65% to $68.9 million in 2025, then declined by 14.36% to $59.0 million in 2026.
- The last three Assets figures came in at $59.0 million (Q1 2026), $68.9 million (Q4 2025), and $54.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 52.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.77 Mn |
| Mar 31, 2026 | 59.02 Mn |
| Dec 31, 2025 | 68.92 Mn |
| Sep 30, 2025 | 54.17 Mn |
| Jun 30, 2025 | 62.12 Mn |
| Mar 31, 2025 | 77.71 Mn |
| Dec 31, 2024 | 110.54 Mn |
| Sep 30, 2024 | 135.16 Mn |
| Jun 30, 2024 | 149.88 Mn |
| Mar 31, 2024 | 167.70 Mn |
| Dec 31, 2023 | 182.39 Mn |
| Sep 30, 2023 | 107.10 Mn |
| Jun 30, 2023 | 98.89 Mn |
| Mar 31, 2023 | 112.55 Mn |
| Dec 31, 2022 | 124.80 Mn |
| Sep 30, 2022 | 64.48 Mn |
| Jun 30, 2022 | 63.63 Mn |
| Mar 31, 2022 | 145.83 Mn |
| Dec 31, 2021 | 171.07 Mn |
| Sep 30, 2021 | 144.69 Mn |